Results 21 to 30 of about 811,174 (190)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

open access: yesMetabolism Open, 2021
Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj   +1 more source

The chemical structures of irreversible BTK inhibitors.

open access: yes, 2023
The chemical structures of irreversible BTK inhibitors.
Amy H. Andreotti (366314)   +1 more
core   +1 more source

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

open access: yesClinical Hematology International, 2022
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh   +4 more
doaj   +1 more source

Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib

open access: yesFrontiers in Pharmacology, 2022
Background: Bruton’s tyrosine kinase (BTK) inhibitors are commonly used in the targeted therapy of B-cell malignancies. It is reported that myelosuppression and fungal infections might occur during antitumor therapy of BTK inhibitors, therefore a ...
Lu Chen   +5 more
doaj   +1 more source

BTK mutation and ibrutinib resistance [PDF]

open access: yes, 2023
Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant ...

core   +2 more sources

Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2022
Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin   +10 more
doaj   +1 more source

Btk inhibitors in atherosclerosis [PDF]

open access: yesBlood, 2018
In this issue of Blood, Busygina et al provide provocative evidence that there is a potential role for Bruton tyrosine kinase (Btk) inhibitors in inhibiting platelet aggregation specifically at the site of unstable atherosclerotic plaques ...
openaire   +2 more sources

The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells

open access: yes, 2008
Activated mast cells are a major source of the eicosanoids PGD(2) and leukotriene C(4) (LTC(4)), which contribute to allergic responses. These eicosanoids are produced following the ERK1/2-dependent activation of cytosolic phospholipase A(2), thus ...
Gilfillan, Alasdair M.   +5 more
core   +2 more sources

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity [PDF]

open access: yes, 2022
In recent years, the introduction of new drugs targeting Bruton’s tyrosine kinase (BTK) has allowed dramatic improvement in the prognosis of patients with chronic lymphocytic leukemia (CLL) and other B-cell neoplasms.
Fiorcari S.   +39 more
core   +2 more sources

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

open access: yesMolecules, 2023
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and ...
Dariusz Rozkiewicz   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy